The estimated economic value of the welfare loss due to prostate cancer pain in a defined population

REFERENCES

• National Board of Health and Welfare. www.sos.se/epc/fs/ index.htm (accessed 4 August 2003).
   Google Scholar
• Swedish Cancer Society, National Board of Health and Welfare. Cancer in figures 2001 (in Swedish). Stockholm: SCS; 2001.
   Google Scholar
• Borre M, Nerstrom B, Overgaard J. The dilemma of prostate cancer. Acta Oncol 1997; 36(7): 681–7.
   Google Scholar
• National Board of Health and Welfare. Cancer incidence in Sweden 1999 Stockholm: Health and Diseases; 2001. p. 4.
   Google Scholar
• Greenwald H, Bonica J, Bergner M. The prevalence of pain in four cancers. Cancer 1987; 60: 2563–9.
   Google Scholar
• Cleeland C, Gonin R, Hatfield A, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994; 330: 592–6.
   PubMed Web of Science ®Google Scholar
• Jonler M, Nielsen 0, Wolf H. Urinary symptoms, potency, and quality of life in patients with localized prostate cancer followed up with deferred treatment. Urology 1998; 52(6): 1055–62.
   Google Scholar
• Lubeck D, Litwin M, Henning J, Stoddard M, Flanders S, Carrol R. Changes in health-related quality of life in the first year after treatment for prostate cancer: results from CaP-SURE. Urology 1999; 53(1): 180–6.
   PubMed Web of Science ®Google Scholar
• Portenoy R, Lesage P. Management of cancer pain. Lancet 1999; 353: 1695–700.
   PubMed Web of Science ®Google Scholar
• Wang X, Cleeland C, Mendoza T, et al. The effects of pain severity on health-related quality of life. Cancer 1999; 86: 1848–55.
   PubMed Web of Science ®Google Scholar
• Krupski T, Petroni G, Bissonette E, Theodorescu D. Quality-of-life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localized prostate cancer. Urology 2000; 55(5): 736–42.
   PubMedGoogle Scholar
• Lame F, Colleau S, Brasseur L, Cleeland C. Multicentre study of cancer pain and its treatment in France. Br Med J 1995; 310: 1034–7.
   PubMedGoogle Scholar
• Cleary P, Morrissey G, Oster G. Health-related quality of life in patients with advanced prostate cancer: a multinational per-spective. Qual Life Res 1995; 4: 207–20.
   Google Scholar
• Sandblom G, Carlsson P, Sigsj6 P, Varenhorst E. Pain and health-related quality of life in a geographically defined population of men with prostate cancer. Br J Cancer 2001; 85(4): 497–503.
   Google Scholar
• Sandblom G, Dufmats M, Olsson M, Varenhorst E. Validity of a population-based cancer register in Sweden an assessment of data reproducibility in the South-East region prostate cancer register. Scand J Urol Nephrol 2003; 37(2): 112–9.
   PubMed Web of Science ®Google Scholar
• The EuroQol Group. EuroQol—a new facility for measure-ment of health related quality of life. Health Policy 1990; 16: 199–208.
   PubMed Web of Science ®Google Scholar
• EuroQol group. EQ-5D. User guide. A measure of health-related quality of life. Rotterdam: EuroQol Business Manage-ment; 1996.
   Google Scholar
• Brooks R, Jendteg S, Lindgren B, Persson U, Björk S. EuroQol: health-related quality of life measurement. Results of the Swedish questionnaire exercise. Health Policy 1991; 18: 37–48.
   Google Scholar
• Chapman R, Stone P, Sandberg E, Bell C, Neuman P. A comprehensive league table of cost-utility ratios and a sub-table of 'panel-worthy' studies. Med Decis Making 2000; 20(4): 451 —67.
   Google Scholar
• Kobelt G, Jonsson L, Henriksson F, Fredrikson S, Jonsson B. Cost-utility analysis of interferon beta-1B in secondary pro-gressive multiple sclerosis. Int J Technol Assess Health Care 2000; 16(3): 768–80.
   Google Scholar
• Johannesson M, Meltzer D. Some reflections on cost-effective-ness analysis. Health Economics 1998; 7: 1–7.
   PubMed Web of Science ®Google Scholar
• Hirth R, Chernew M, Miller E, Fendrick A, Weissert W. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000; 20: 332–42.
   Google Scholar
• Newhouse JP. US and UK health economics: two disciplines separated by a common language? Health Economics 1998; 7: S79–92.
   PubMedGoogle Scholar
• Gyrd-Hansen D. Willingness to pay for a QALY. Health Economics 2003; 12: 1049–60.
   PubMed Web of Science ®Google Scholar
• Neighbors D, Bell T, Wilson J, Dodd S. Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain. Pain Symptom Manage 2001; 21(2): 129–43.
   PubMedGoogle Scholar
• Sennfält K, Carlsson P, Thorfinn J, Frisk J, Henriksson M, Varenhorst E. Technological changes in the management of prostate cancer result in increased healthcare costs. Scand J Urol Nephrol 2003; 37: 226–31.
   Google Scholar
• Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995; 61: 277–84.
   Google Scholar
• George B, Harris A, Mitchell A. Cost effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia 1991–96. Centre for Health Program Evaluation. Working Paper 1999, p. 89.
   Google Scholar